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Abstract
Background Takotsubo cardiomyopathy often presents
with the clinical signs of ST-elevation myocardial in-
farction (STEMI). The increase in scientific publications
addressing this relatively rare condition may result in higher
awareness and diagnosis of takotsubo cardiomyopathy.
Aim To assess the observed prevalence per year of tako-
tsubo cardiomyopathy in a large registry of patients with
STEMI, during a 12-year inclusion period.
Method All patients presenting with STEMI at a large re-
gional cardiology clinic were entered into a database (n =
8,413, mean age 63 ± 13 years). Takotsubo cardiomyopathy
was diagnosed in 42 patients (0.5 %). Years of evaluation
were defined as ‘early years’ (January 2002 to December
2007; n = 4350) and ‘later years’ (January 2008 to Decem-
ber 2013). Multivariable analyses were performed to adjust
for differences in demographical and clinical variables.
Results In later years, the age of STEMI patients was
slightly higher (64 ± 13 vs. 63 ± 13 years, p < 0.001),
with more patients with clinical symptoms of shock (10
vs. 7 %, p < 0.001) or a history of percutaneous coronary
intervention or hypertension (10 vs. 8 %, p = 0.001 and 37
vs. 34 %, p < 0.001). Smoking and a positive family history
were less often observed during later years (39 vs. 46 %,
p < 0.001 and 37 vs. 42 % p < 0.001). Patients with tako-
tsubo cardiomyopathy were more often female (81 vs.
27 %, p = 0.001). Takotsubo cardiomyopathy was more
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often diagnosed in the later period (0.7 vs. 0.3 %, OR 2.4,
95 % CI 1.2–4.6, p = 0.009). The higher prevalence of tako-
tsubo cardiomyopathy in recent years remained significant
after adjustment for differences in patient characteristics
(OR 2.1, 95 % CI 1.1–4.3).
Conclusion Takotsubo cardiomyopathy is currently more
often diagnosed in patients with STEMI compared with in
earlier years. This is probably due to the increased scientific
and clinical awareness among doctors, but the prevalence
is still low.
Keywords Takotsubo cardiomyopathy · Gender · STEMI
Introduction
Takotsubo cardiomyopathy is characterised by transient
wall motion abnormalities mimicking ST-elevation my-
ocardial infarction (STEMI). It was first described in Japan
in 1991 [1]. At that time, takotsubo cardiomyopathy was
completely unrecognised in Europe and North America
and it was thought to only occur in Asia, where the first
cohorts were published approximately 10 years later [2,
3]. The first observation of takotsubo cardiomyopathy in
Caucasian patients was published in 2003 [4]. Since then,
awareness of takotsubo cardiomyopathy among cardiolo-
gists in Europe and North America has increased, with
more patients initially presenting with STEMI being diag-
nosed with takotsubo cardiomyopathy. However, it is also
likely that a distinctly different population of patients are
referred for STEMI over time due to improved therapy,
logistics and modifications in referral [5, 6]. This may
contribute to a shift in the observed numbers of takotsubo
cardiomyopathy. For instance, as currently more elderly
women with STEMI are referred for immediate percuta-
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neous coronary intervention (PCI), the number of observed
cases of takotsubo cardiomyopathy may have increased,
since it is more prevalent in postmenopausal women [7, 8].
To assess alterations in the observed prevalence of tako-
tsubo cardiomyopathy in patients with STEMI, adjustments
should be made for these potential confounding factors [3,
9, 10]. In the current study, we investigated whether the
observed number of patients with takotsubo cardiomyopa-
thy changed over a 12-year period and if this is related to
alterations in patient characteristics.
Methods
From January 2002 to December 2013, individual data
from all STEMI patients who were considered for primary
PCI and who underwent early coronary angiography at our
centre, were prospectively recorded in a dedicated database.
Early years were defined as January 2002 until December
2007 and later years as January 2008 until December 2013.
Patients were diagnosed with STEMI if they had chest
pain lasting longer than 30 minutes and ECG changes with
ST elevation >2 mm in at least two precordial leads or
>1 mm in the limb leads. Cardiac biomarkers were ele-
vated in all patients. Information on demographic variables
was directly registered at first contact with the patient,
including age, sex, medical history, family history and
traditional cardiovascular risk factors. In patients in whom
echocardiography was performed during admission or
after one month to assess LV function, the echocardiogram
was reviewed by an expert cardiologist or a resident in car-
diology supervised by an expert. In order to investigate the
number of publications concerning takotsubo cardiomyopa-
thy, we sought in the PubMed database with the following
search strategy per year: (“2002/01/01” [Date-Publication] :
“2002/12/31” [Date-Publication]) AND ((tako AND tsubo)
OR takotsubo). Although takotsubo cardiomyopathy is
sometimes mentioned as ‘ampulla cardiomyopathy’, ‘api-
cal ballooning syndrome’, ‘broken heart’ or ‘stress-induced
cardiomyopathy’ in the literature, almost all articles were
still revealed with the search strategy because takotsubo or
tako tsubo was mentioned in the article [11–13].
Definition of takotsubo
ECG changes (either ST-segment elevation and/or T-wave
inversion) are major diagnostic criteria for takotsubo car-
diomyopathy. Since all patients in our database had ST
elevation, this criterion was fulfilled for all patients. The
presence of an epicardial stenosis or spasm of a coronary
artery perfusing the territory of hypokinesia or akinesia of
the myocardium are exclusion criteria for takotsubo car-
diomyopathy [7, 14]. Patients with takotsubo cardiomy-
opathy had transient hypokinesia, dyskinesia or akinesia of
the LV mid segments with or without apical involvement
according to the diagnostic criteria of the Mayo Clinic [10].
Statistical analysis
Statistical analysis was performed using SPSS version 20
(SPSS Inc, Chicago, IL). Continuous data were expressed
as mean and standard deviation and categorical data as per-
centages. Tests for significance were two-sided and values
with an α of 0.05 were considered significant. In order
to analyse whether an independent association was present
for the number of patients observed with takotsubo car-
diomyopathy over time and the number of publications, we
used binary logistic regression comparing early years with
later years. The multivariate model consisted of all baseline
variables with a p ≤ 0.1 (gender, age, previous PCI, hyper-
tension, smoking, hypercholesterolaemia, positive family
history and Killip class ≥2).
Results
In total, 8,413 patients with a STEMI were referred to our
centre during a 12-year time period. The mean age was
63 ± 13 years. During the study period, 685 (8 %) patients
had no identifiable stenosis or spasm of a coronary artery
at angiography. These patients may have had takotsubo
cardiomyopathy according to the Mayo Clinic’s diagnos-
tic criteria [10]. All patients had a complete resolution of
the myocardial segments on echocardiography or angiogra-
phy within a month. Two patients with myocarditis were
excluded and there were no patients with pheochromocy-
toma. Of these 685 patients, one month follow-up data on
left ventricular function were missing in two patients from
2002, therefore they were excluded from further analysis.
In total, 42 patients (0.5 %) were diagnosed with takotsubo
cardiomyopathy according to the criteria as described in the
methods.
The 643 patients who were treated conservatively and
did not have takotsubo cardiomyopathy were older than
invasively treated patients (65 ± 16 vs. 63 ± 12 years, p =
0.002). They were also more often female (31 vs. 27 %, p =
0.01), more often had a history of myocardial infarction (15
vs. 10 %, p < 0.001), a history of coronary artery bypass
graft (9 vs. 3 %, p < 0.001), a history of PCI (12 vs. 9 %, p =
0.02), a history of cerebrovascular accident (6 vs. 3 %, p <
0.001), hypertension (41 vs. 36 %, p = 0.007) and diabetes
(14 vs. 11 %, p = 0.03). Patients treated conservatively less
often had a positive family history (31 vs. 40 %, p < 0.001)
and were less often smokers (30 vs. 44 %, p < 0.001).
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Age 63 ± 13 64 ± 13 0.001
Gender (women) 1,165 (27 %) 1,154 (28 %) 0.10
Observed takotsubo cardiomyopathy 13 (0.3 %) 27 (0.7 %) 0.007
BMI (kg/m2) 27 ± 5 28 ± 8 0.20
History of MI 441 (10 %) 412 (10 %) 0.88
CABG 156 (4 %) 135 (3 %) 0.56
PCI 356 (8 %) 414 (10 %) 0.001
Stroke 129 (3 %) 134 (3 %) 0.36
Diabetes 508 (12 %) 458 (11 %) 0.59
Hypertension 1,454 (34 %) 1,557 (37 %) <0.001
Positive family history 1,710 (42 %) 1,413 (37 %) <0.001
Smoking (ever) 1,925 (46 %) 1,557 (39 %) <0.001
Hypercholesterolaemia 958 (23 %) 840 (22 %) 0.07
Killip class >2 on admission 302 (7 %) 283 (10 %) <0.001
Hospital stay (days) 4 ± 6 5 ± 8 <0.001
Heart frequency (min) 76 ± 18 76 ± 19 0.023
Systolic BP at admission (mmHg) 133 ± 25 132 ± 27 0.70
Diastolic BP at admission (mmHg) 80 ± 16 80 ± 23 0.78
BMI body mass index, BP blood pressure, CABG coronary artery bypass graft, MI myocardial infarction, PCI percutaneous coronary intervention
Trends over the years in patients referred for
STEMI
Compared with earlier years, patients referred for STEMI
between 2008–2013 were older and more often had a his-
tory of previous PCI, hypertension, and a higher Killip class
at admission. Current smoking and a positive family his-
tory were less often present in later years. Furthermore,
the duration of hospital stay was slightly longer in the later
period. The other clinical characteristics including gender
did not change over time (Tab. 1).
Difference in patients with and without takotsubo
Patients with takotsubo cardiomyopathy were more often
older, female, less often current smokers and had a higher
heart rate at admission compared with the usual STEMI
patients (Tab. 2). All other cardiovascular risk factors and
haemodynamic parameters were comparable between pa-
tients with and without takotsubo cardiomyopathy.
Trends in prevalence of takotsubo cardiomyopathy
over the years
The annual observed prevalence of takotsubo cardiomy-
opathy in patients with STEMI ranged from 0 % in 2002
to 1.05 % in 2009 and increased significantly over time
(Fig. 1). Compared with the number of patients with tako-
tsubo cardiomyopathy in the early years, takotsubo car-
diomyopathy was more often observed in the later period
(OR 2.4, 95 % CI 1.2–4.6). In the multivariate model, this
difference remained significant (OR 2.1, 95 % CI 1.1–4.3).
The literature search showed that in the early years,
takotsubo was less often mentioned in the literature com-
pared with later (Fig. 2).
Discussion
In this large cohort of patients with STEMI, we found a sig-
nificant increase in the number of patients observed with
takotsubo cardiomyopathy over time, independent of pa-
tient characteristics. However, the prevalence of takotsubo
cardiomyopathy among STEMI patients is still low.
The prevalence of takotsubo cardiomyopathy in the liter-
ature ranges from 0.02 % in the general population [14] to
1–2 % in populations with acute coronary syndromes [7].
However, these prevalences cannot be compared with our
study because we present a cohort of patients with STEMI.
To our knowledge, this is the first STEMI population to be
studied for takotsubo cardiomyopathy.
The increased number of observed takotsubo cardiomy-
opathy patients over the years may have different expla-
nations. Firstly, since patients with STEMI are currently
older and takotsubo cardiomyopathy is associated with in-
creasing age, takotsubo cardiomyopathy may be more often
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Age 63 ± 13 66 ± 13 0.13
Gender (women) 2,285 (27 %) 34 (81 %) <0.001
BMI (kg/m2) 28 ± 13 25 ± 4 0.22
History of MI 850 (10 %) 3 (7 %) 0.54
CABG 291 (4 %) 0 (0 %) 0.23
PCI 769 (9 %) 1 (2 %) 0.13
Stroke 261 (3 %) 2 (5 %) 0.53
Diabetes 963 (12 %) 3 (7 %) 0.40
Hypertension 2,999 (36 %) 12 (29 %) 0.35
Positive family history 3,113 (39 %) 10 (25 %) 0.08
Smoking (ever) 3,477 (43 %) 5 (12 %) <0.001
Hypercholesterolaemia 1,792 (22 %) 6 (15 %) 0.24
Killip class ≥2 on admission 582 (8 %) 3 (9 %) 0.80
Hospital stay (days) 4 ± 7 3 ± 3 0.21
Heart rate (min) 76 ± 21 83 ± 15 0.04
Systolic BP on admission (mmHg) 133 ± 27 135 ± 29 0.47
Diastolic BP on admission (mmHg) 76 ± 19 80 ± 15 0.90
BMI body mass index, BP blood pressure, CABG coronary artery bypass graft, MI myocardial infarction, PCI percutaneous coronary intervention
diagnosed [15–17]. However, this cannot be the entire ex-
planation for the increased number of observed cases of
takotsubo cardiomyopathy, because after correcting for age
in the multivariate model there was still a relationship be-
tween later years and increase of takotsubo cardiomyopathy
in our study. Another explanation for this increase may be
changed risk profiles of admitted STEMI patients over the
years, which was also observed in other studies [18, 19].
These changes in risk factors only partly explain the differ-
ence in observed frequency of takotsubo cardiomyopathy
in our study, since after multivariable analyses takotsubo
cardiomyopathy was still more prevalent in recent years.
A third and probably most important reason for the in-
creased prevalence may be the improved network and fa-
cilities in the treatment of acute STEMI patients. In fact,
almost all STEMI patients are currently referred to a tertiary
centre with primary PCI facilities. Furthermore, improved
recognition of takotsubo cardiomyopathy may also play an
important role, which may be related to a higher aware-
ness of cardiologists and other medical personnel due to
an increasing number of scientific studies on takotsubo car-
diomyopathy in the literature and communications at con-
ferences (Fig. 2). Large systemic registries or multicentre
trials [20–22] do not only increase awareness, they also
result in a better understanding of the demographics and
ultimately also the treatment of takotsubo cardiomyopa-
thy. Furthermore, case reports concerning a new clinical
presentation of takotsubo cardiomyopathy are more often
published [23, 24].
In our study, LV function was assessed with an echo or
LV angiogram primarily in the acute situation after STEMI.
Therefore, we used only LV function assessment in the
acute setting. However, standard evaluation of LV function
both acutely and after one month can avoid misdiagnosis
of takotsubo cardiomyopathy. The ESC guidelines also rec-
ommend evaluation of resting LV function both acutely and
after more than two weeks after STEMI [25]. If the outpa-
tient LV assessment is performed four weeks after STEMI,
most takotsubo cardiomyopathy patients can be diagnosed
with more certainty, because LV function due to takotsubo
cardiomyopathy should be normalised within four weeks
according to the definition of takotsubo cardiomyopathy
[26].
Although we evaluated each STEMI patient without
coronary intervention for possible takotsubo cardiomyopa-
thy, only 0.5 % of all patients with STEMI admitted in our
hospital were diagnosed as takotsubo cardiomyopathy. Our
observed prevalence of takotsubo cardiomyopathy is lower
than estimates in the literature and therefore it is likely that
we may have underdiagnosed takotsubo cardiomyopathy in
our database [9, 27, 28]. Particularly in patient groups with
a high prevalence of coronary artery disease, takotsubo
cardiomyopathy may be underdiagnosed. As both coro-
nary artery disease and takotsubo cardiomyopathy might
be present in these patients and takotsubo cardiomyopathy
can only be diagnosed in the absence of a significant coro-
nary artery stenosis, takotsubo cardiomyopathy may not be
recognised [27].
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Fig. 1 Percentage of observed takotsubo presentiegeld as STEMI
Fig. 2 Number of publications in PubMed with takotsubo in the title
It is important to discriminate takotsubo cardiomyopathy
with heart failure from STEMI with heart failure because it
may have major implications for treatment.
Firstly, although it has not been properly studied, medi-
cal treatment for systolic heart failure can be considered in
takotsubo cardiomyopathy patients in order to relieve acute
symptoms (e. g. oedema) [29]. Three important drugs to
use to these patients are mineralocorticoid receptor antag-
onists, beta blockers and angiotensin-converting enzyme
(ACE) inhibitors (or angiotensin receptor blocker) [30].
When LV function normalises in patients with takotsubo
cardiomyopathy after one month, it could be considered to
stop the ACE inhibitor and mineralocorticoid-receptor an-
tagonist to avoid adverse events associated with these drugs
[31]. Although evidence is limited, the continuation of
beta blockers can be considered in patients with takotsubo
cardiomyopathy, because of the theory that takotsubo car-
diomyopathy is caused by sympathetic hyperactivity [32].
Secondly, temporal aggressive heart failure treatment as
LV assist devices may be considered in takotsubo cardiomy-
opathy patients if needed, even if the patient is not a can-
didate for heart transplant [33]. Misdiagnosing takotsubo
cardiomyopathy for type 1 myocardial infarction may re-
sult in an unnecessary, long-term treatment with dual an-
tiplatelet therapy. Without plaque rupture, only long-term
prescription of acetylsalicylic acid is indicated and without
coronary artery disease no antiplatelet therapy at all should
be given in takotsubo cardiomyopathy patients. This will
potentially diminish bleeding complications [34]. Finally,
since takotsubo cardiomyopathy has a good prognosis in
most patients, especially after four weeks, when the LV
function normalises, patients may receive more adequate
information about their prognosis.
There are several opportunities to improve the diagno-
sis of takotsubo cardiomyopathy. First of all, increased
awareness in doctors and (possibly) patients is necessary.
Moreover, a history of emotional trigger(s) must prompt the
doctor to include takotsubo cardiomyopathy in the differen-
tial diagnosis. This is especially so in elderly women pre-
senting with STEMI, because the prevalence of takotsubo
cardiomyopathy is highest in this patient group [10]. The
evaluation of possible emotional triggers should be done
routinely in every patient with STEMI. Furthermore, when
coronary stenosis but not coronary occlusion is observed
with invasive angiography, fractional flow reserve could be
considered in a later phase to evaluate whether the stenosis
is haemodynamically significant. If no epicardial coronary
stenosis is found as the cause of the STEMI at coronary
angiography, apart from routine echocardiography, LV an-
giography can visualise an apical ballooning pattern of the
left ventricle.
Study limitations
This study was performed retrospectively in the first years
and not all patients received sequential imaging of LV func-
tion. Therefore, it is likely that especially patients with
takotsubo cardiomyopathy were underdiagnosed.
Conclusions
We observed an increased frequency of takotsubo car-
diomyopathy over the years. Since this difference re-
mained irrespective of classical cardiovascular risk factors,
and since takotsubo cardiomyopathy received more atten-
tion in the literature in the course of this study, it is likely
that raised awareness contributed to this increase. National
registries for patients with takotsubo cardiomyopathy may
further increase awareness and stimulate scientific research
about aetiology and (medical) treatment of takotsubo car-
diomyopathy.
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